Despite semaglutide’s proven efficacy, a recent Danish study has revealed a surprising reality: over half of adults stop using the drug within a year. While highly effective at curbing appetite and promoting weight loss, semaglutide’s high cost, side effects like nausea, and potential health complications lead many to discontinue treatment. Younger adults, men, and those in low-income areas are especially prone to quitting, raising concerns as stopping the medication often results in weight regain. These findings underscore the critical challenges of maintaining long-term adherence to GLP-1 receptor agonists. Addressing these barriers, such as affordability and equitable access, will be essential to fully harness the potential of these breakthrough drugs in combatting the obesity epidemic.

References

Half Quit “Miracle” Weight-Loss Shots Ozempic and Wegovy Within One Year [Internet]. SciTechDaily. 2025 [cited 2025 Sep 22].